Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence

Cell Cycle

Volumn 8, Issue 15, 2009, Pages 2425-2434

  Mele, Deanna A ^a   Bista, Pradeep ^a   Baez, Diana Velez ^a   Huber, Brigitte T ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c Myc; Cell cycle entry; p53; Protease inhibitor; shRNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIPEPTIDYL PEPTIDASE; P21 ACTIVATED KINASE; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN P53;

APOPTOSIS; ARTICLE; BLOOD CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; DOWN REGULATION; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; ONCOGENE C MYC; PROTEIN EXPRESSION; RETINOBLASTOMA;

EID: 68449091581     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.15.9144     Document Type: Article

References (68)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1:222-231 (Pubitemid 33741897)
3. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246:629-634
4. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 2003; 371:525-532 (Pubitemid 36547636)
5. Underwood R, Chiravuri M, Lee H, Schmitz T, Kabcenell AK, Yardley K, Huber BT. Sequence, purification and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 1999; 274:34053-34058 (Pubitemid 129511738)
6. Chiravuri M, Schmitz T, Yardley K, Underwood R, Dayal Y, Huber BT. A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol 1999; 163:3092-3099 (Pubitemid 29431806)
7. Tanchot C, Lemonnier FA, Perarnau B, Freitas AA, Rocha B. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 1997; 276:2057-2062 (Pubitemid 27443614)
8. Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubartelli A, et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996; 85:345-356 (Pubitemid 26160706)
9. Classon M, Dyson N. p107 and p130: versatile proteins with interesting pockets. Exp Cell Res 2001; 264:135-147 (Pubitemid 32989088)
10. Ho A, Dowdy SF. Regulation of G(1) cell cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002; 12:47-52.
11. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-573
12. Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79:487-496
13. Mulligan GJ, Wong J, Jacks T. p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol 1998; 18:206-220 (Pubitemid 28021032)
14. 1 cell state. Mol Cell Biol 1996; 16:6965-6976
15. Vairo G, Livingston DM, Ginsberg D. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev 1995; 9:869-81.
16. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene 1999; 18:7873-82.
17. Kip1 regulates T cell proliferation. J Biol Chem 2001; 276:21976-83.
18. Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J Biol Chem 2002; 277:31263-9.
19. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14:145-55.
20. Kip1. J Immunol 2001; 166:952-8.
21. Romerio F, Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. Faseb J 2002; 16:1680-2.
22. Villanueva J, Yung Y, Walker JL, Assoian RK. ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 2007; 18:1457-63.
23. Whitehurst CE, Boulton TG, Cobb MH, Geppert TD. Extracellular signal-regulated kinases in T cells. Anti-CD3 and 4 beta-phorbol 12-myristate 13-acetate-induced phosphorylation and activation. J Immunol 1992; 148:3230-7.
24. kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002; 168:2729-36.
25. + T cells. Science 1996; 271:1276-8.
26. + T cells. Science 1996; 271:1272-6.
27. Alberola-Ila J, Forbush KA, Seger R, Krebs EG, Perlmutter RM. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 1995; 373:620-3.
28. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286:1374-7.
29. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002; 529:122-5.
30. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9:113-8.
31. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407:645-8.
32. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001; 12:337-49.
33. Bista P, Mele DA, Baez DV, Huber BT. Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Mol Immunol 2008.
34. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983; 35:603-10.
35. Schwartz RH. T cell clonal anergy. Curr Opin Immunol 1997; 9:351-7.
36. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94.
37. Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3:552-8.
38. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-5.
39. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-805.
40. Crook T, Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992; 11:3935-40.
41. Crook T, Marston NJ, Sara EA, Vousden KH. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 1994; 79:817-27.
42. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 1993; 8:2159-66.
43. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
44. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6:1915-22.
45. Dang CV. c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 1999; 19:1-11.
46. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33:401-6.
47. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95.
48. Vousden KH. Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2002; 2:351-2.
49. Roussel MF, Theodoras AM, Pagano M, Sherr CJ. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 1995; 92:6837-41.
50. Massague J. G1 cell cycle control and cancer. Nature 2004; 432:298-306.
51. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359:554-6.
52. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
53. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419:729-34.
54. Kip1 expression is required for development and function of T cells. J Immunol 2001; 166:304-12.
55. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001; 2:1174-82.
56. Buckley AF, Kuo CT, Leiden JM. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc - dependent pathway. Nat Immunol 2001; 2:698-704.
57. Kuo CT, Veselits ML, Leiden JM. LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. Science 1997; 277:1986-90.
58. Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NFkappaB, c-Myc and pRb pathways. J Immunol 2001; 167:6021-30.
59. Chiravuri M, Agarraberes F, Mathieu SL, Lee H, Huber BT. Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol 2000; 165:5695-702.
60. DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, et al. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 1998; 160:4175-81.
61. Levens DL. Reconstructing MYC. Genes Dev 2003; 17:1071-7.
62. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109:295-9.
63. L. Immunity 1995; 3:87-98.
64. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001; 20:1688-702.
65. Alexander K, Yang HS, Hinds PW. pRb inactivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol Cancer Res 2003; 1:716-28.
66. Wan YY, DeGregori J. The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. Immunity 2003; 18:331-42.
67. 0 programme in chronic lymphocytic leukaemia: a novel prognostic factor. Br J Haematol 2005; 128:472-81.
68. Chiravuri M, Lee H, Mathieu SL, Huber BT. Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase. J Biol Chem 2000; 275:26994-9.